Active Litigation
Kratom Lawsuit Facts
TorHoerman Law is investigating claims for the Kratom Lawsuit.
Active Litigation
TorHoerman Law is investigating claims for the Kratom Lawsuit.
A 7-OH kratom injury lawsuit may be available to someone who suffered serious harm after using a concentrated 7-hydroxymitragynine product and has grounds to pursue a claim against its manufacturer, distributor, or seller.
Concentrated 7-OH products are sold as tablets, gummies, liquid shots, and other formulations containing substantially more 7-hydroxymitragynine than natural kratom leaf.
The Food and Drug Administration (FDA) has warned about addiction, seizures, withdrawal symptoms, and other adverse health effects associated with concentrated 7-OH products. Medical toxicologists have also identified public health risks involving respiratory depression, overdose, and death.
Claims may involve allegedly inadequate warnings, misleading descriptions of product strength or safety, or defective formulations that contributed to an injury.

7-hydroxymitragynine, often abbreviated 7-OH, is an opioid-active compound found in trace amounts in the kratom plant.
Some companies advertise enhanced 7-OH products for relaxation, pain relief, chronic pain, or relief from opioid withdrawal. The FDA has not approved 7-OH for any medical use.
A person who experiences seizures, serious breathing problems, severe dependence, or other significant harm after using these products may have a potential injury claim.
An injury after 7-OH use does not, by itself, establish liability. Consumers can seek a case review without identifying every potential defendant or obtaining a definitive medical opinion about causation.
Our attorneys investigate potential 7-OH injury and wrongful death claims as part of our kratom lawsuit practice.
We review the product’s ingredients and warnings, how it was marketed, the person’s exposure history, and the available medical evidence.
Contact TorHoerman Law for a free, confidential consultation, or use the chat feature on this page to discuss a potential 7-OH injury claim.
7-OH lawsuits may allege that manufacturers and sellers failed to warn consumers adequately about concentrated products’ opioid-like effects, potency, and risks of addiction or overdose.
Other allegations may concern undisclosed ingredients, contaminated or defective products, or marketing that presented concentrated 7-OH as equivalent to traditional kratom leaf.
The product’s formulation, labeling, and marketing may affect which legal claims are available and which companies may be responsible.
Yes. In July 2026, the estate of James Patrick Mills filed a North Carolina wrongful death lawsuit alleging that kratom and concentrated 7-OH products sold through smoke shops contributed to his death.
The complaint named sellers and manufacturers, including Hydroxie, LLC, and alleged failures involving product warnings and marketing.
The underlying complaint appears as an exhibit to the September 2026 federal insurance-coverage action Kinsale Insurance Company v. Hydroxie, LLC. That insurance dispute is separate from the wrongful death case.
The allegations have not been established as findings of medical causation or liability.
An April 2025 California class action against Thang Botanicals and FTLS Holdings separately raised allegations concerning the marketing of 7-OH products.
That consumer-marketing case is distinct from a personal injury or wrongful death claim.
People who developed serious medical complications after using a concentrated 7-OH product may qualify for an investigation into a product liability or other legal claim.
A diagnosis or product name alone does not determine eligibility.
Factors that may support a 7-OH lawsuit investigation include:
A person does not need to prove every element of a lawsuit before seeking legal advice.
Someone hospitalized with severe breathing problems after taking an identifiable 7-OH tablet, for example, may have grounds to seek a review even while other possible causes remain under investigation.
Brief nausea or temporary dizziness without substantial harm generally presents a different situation from an injury requiring emergency or ongoing treatment.
7-hydroxymitragynine is one of several kratom alkaloids found in Mitragyna speciosa, a tropical tree native to Southeast Asia.
The main alkaloid, mitragynine, accounts for much more of natural kratom leaf than 7-OH, which generally occurs in trace amounts.
The body produces 7-OH as a key active metabolite of mitragynine. Manufacturers can also convert mitragynine into additional 7-OH for concentrated products.
Both compounds interact with mu-opioid receptors involved in pain signaling, sedation, and breathing. Their clinical pharmacology, psychoactive effects, and potential risks differ.
Laboratory studies have characterized these compounds as partial agonists at mu-opioid receptors under certain experimental conditions. Receptor activity alone does not establish their effects or abuse liability in humans.
A 2016 laboratory study measured 7-OH as approximately ten times more potent than mitragynine in a human mu-opioid receptor activation assay.
That laboratory comparison does not establish that a consumer product is ten times as strong in humans or that its overdose risk is ten times greater.
Animal studies have identified analgesic effects, but no concentrated 7-OH product has demonstrated proven therapeutic effects in humans or received FDA approval for treatment.
Traditional kratom powder and kratom capsules generally contain botanical leaf material with a mixture of naturally occurring alkaloids. New York State clinical guidance describes 7-OH levels in natural dried kratom leaf as typically below 0.05% by weight, although that is not a universal limit for all products.
Different kratom preparations have different alkaloid profiles. Extracts may concentrate specific compounds, while 7-OH tablets, gummies, shots, and enhanced products may contain added or substantially higher amounts of 7-OH.
Some products also contain related compounds, including mitragynine pseudoindoxyl, which can complicate product identification and toxicology questions.
The FDA distinguishes concentrated 7-OH products from natural kratom leaf when discussing its targeted enforcement and scheduling recommendations.
Kratom safety concerns involving botanical products include seizures, dependence, and liver toxicity, but these reported effects should not automatically be attributed to isolated 7-OH. The composition and risks of traditional kratom and 7-OH concentrates can differ substantially.
The brand name alone may not reveal which alkaloids a product contains or their concentrations.
The American College of Medical Toxicology (ACMT) identifies public health risks involving acute intoxication, respiratory depression, dependence, kratom withdrawal, overdose, and death.
Concentrated 7-OH exposure may cause acute adverse health effects during intoxication and longer-term problems such as tolerance and dependence after repeated use. Research on its full range of chronic effects in humans remains limited.
The FDA has received reports of adverse events involving seizures, nausea, vomiting, confusion, anxiety, depression, and other symptoms following 7-OH exposure.
These reports are signals for further investigation, not proof that 7-OH caused each reported symptom.
Reports of kratom-related liver damage have involved products with different formulations. Current human evidence does not establish that isolated 7-OH carries the same liver risks.
High doses of concentrated 7-OH may produce effects associated with potent opioid products, including profound sedation and impaired breathing.
Respiratory depression occurs when breathing becomes dangerously slow or ineffective and can progress to oxygen deprivation or loss of consciousness. Medical records documenting breathing support may be relevant to a kratom overdose lawsuit.
Potential signs of a severe 7-OH reaction include:
Medical toxicologists advise consumers to avoid mixing kratom-derived 7-OH products with alcohol, benzodiazepines, prescription opioids, or other sedatives because combining them may increase the risk of respiratory depression and fatal overdoses.
People at risk of opioid-like overdose should have access to naloxone and know how to administer naloxone. Emergency responders may also need to provide airway and breathing support.
Naloxone does not replace emergency medical care, and other substances may complicate the response.
If someone is unconscious, breathing abnormally, or suspected of experiencing an overdose, call 911 immediately.
Repeated use of concentrated 7-OH may lead to tolerance, kratom dependence, and withdrawal symptoms when a person reduces or stops use.
People stopping regular high-dose use can experience withdrawal symptoms similar to those of opioid withdrawal, including insomnia, anxiety, restlessness, sweating, muscle aches, nausea, gastrointestinal distress, and cravings.
Some kratom users develop problematic, compulsive use patterns sometimes described as kratom use disorder. Physical dependence is not the same as a substance use disorder, although the conditions can overlap.
Treatment for 7-OH dependence should be individualized according to withdrawal severity, other substance use, physical and mental health, and the patient’s goals. Medical supervision is advisable for people experiencing severe withdrawal or trying to stop prolonged high-dose use.
The ACMT reports that clinicians have treated some patients with 7-OH dependence or withdrawal using medications for opioid use disorder, including buprenorphine or methadone. Published case reports describe inpatient medically managed withdrawal, while another report describes treatment after prolonged high-dose use.
Addiction care may include counseling, behavioral therapy, and follow-up appointments based on the person’s needs. Regular therapy sessions can help some patients, but they are not an established requirement for every recovery.
People who used 7-OH to manage chronic pain or opioid use disorder may need treatment for those conditions as well.
A lawsuit involving severe dependence or withdrawal may allege that a manufacturer or seller inadequately warned about addiction risks or misleadingly marketed the product as a safe alternative.
Dependence alone does not establish a defective product or legal liability.
Seizures, altered mental status, agitation, and psychological symptoms have been reported after exposure to concentrated 7-OH products.
In a September 2025 Texas health advisory, state officials reported 19 poison-center exposures involving concentrated 7-OH products through August 27, 2025; 11 involved serious illnesses or symptoms requiring treatment at a health care facility.
The reports document serious reactions following exposure, although they do not establish that 7-OH was the sole cause in every case.
Doctors may review neurological history, prescription medications, other substance exposures, and diagnostic findings when evaluating a possible connection.
Federal regulators have raised public health concerns about concentrated 7-OH products sold as conventional foods, dietary supplements, or unapproved drugs.
The FDA states that added 7-OH cannot lawfully be used in conventional foods or marketed as a dietary supplement ingredient. No 7-OH drug product has FDA approval.
The FDA has separately concluded that dietary supplements containing kratom are adulterated under federal law because of insufficient safety information.
Major federal developments include:
The October notice was a proposal, not a completed scheduling order for 7-OH. It stated that a temporary order could be published on or after November 13, 2026.
Natural kratom leaf is not federally scheduled under the Controlled Substances Act, although state restrictions may apply.
The Drug Enforcement Administration (DEA) identifies kratom as a Drug and Chemical of Concern, a designation distinct from federal controlled-substance scheduling.
Some states prohibit kratom or particular 7-OH formulations, while others regulate manufacturing, labeling, or sales; the rules governing any product depend on the jurisdiction and date.
The American Kratom Association advocates for state-level kratom regulation, but its position does not determine the legal status or safety of a particular product.
The October proposal set thresholds intended to distinguish concentrated products from natural botanical preparations; it did not find products below those thresholds safe.
The applicable federal and state restrictions depend on the product and the date of sale.
Regulatory actions may support an investigation into a company’s practices, but they do not alone establish that a product caused someone’s injury.
Concentrated 7-OH products have been offered through online stores, smoke shops, vape shops, gas stations, and convenience stores.
Some companies have advertised these products as kratom derivatives or natural alternatives for pain relief, relaxation, or opioid withdrawal, despite their potent opioid-like effects.
The FDA has not approved 7-OH to treat opioid addiction or opioid use disorder.
A 2025 study in Drug and Alcohol Dependence cataloged 304 products sold online containing 7-OH, mitragynine pseudoindoxyl, or both.
Researchers identified frequent marketing claims involving relaxation, focus, and other purported effects. In an individual lawsuit, those claims may be compared with the product’s ingredients, labeling, and available safety evidence.
Potential claims may involve inaccurate potency disclosures, missing warnings about overdose or dependence, undisclosed ingredients, or allegedly misleading claims about safety and abuse liability.
The evidence must concern the product and company involved in the individual claim.
Potential defendants may include manufacturers, importers, distributors, online sellers, retailers, or companies responsible for allegedly misleading labeling or advertising.
Whether a claim is available depends on the product, the alleged misconduct, the injury, and applicable state law.
Legal theories that may arise in a 7-OH case include:
An FDA warning letter concerning a defendant may be relevant evidence, but it does not independently prove that the product was defective or caused an injury.
A wrongful death lawsuit may be available when someone dies following concentrated 7-OH exposure and the evidence supports a legally recognized claim involving a manufacturer or seller.
Severe 7-OH intoxication may involve respiratory depression and other complications. Determining whether the product contributed to a death often requires reviewing other substances and medical conditions.
Evidence may include autopsy and toxicology findings, emergency medical records, product packaging, purchase histories, and witness accounts.
A positive toxicology finding alone does not establish that a particular 7-OH product caused the death.
The individuals authorized to bring a wrongful death or related survival claim, the available damages, and the filing deadline depend on state law.
A medical examiner’s findings may help assess the role of 7-OH, other drugs, and possible contributing conditions.
Product identification is particularly important when similar-looking 7-OH items contain different amounts of active compounds.
You can request a case review without the original container or receipt. Purchase histories, photographs, and other records may help identify the product.
Evidence may include:
Preserve any remaining product and related records without altering or discarding them.
Independent testing may be relevant if a claim involves suspected contamination or differences between labeled and actual potency.
Personal injury and wrongful death statutes of limitations vary by jurisdiction and may begin at different times depending on the nature of the claim.
The date of exposure, onset of symptoms, diagnosis, or death may be relevant, but a delayed diagnosis does not automatically extend the deadline.
An attorney can assess which law applies and whether a claim may still be filed while records and product information are available.
A person with a successful claim may recover medical expenses, lost earnings, reduced earning capacity, pain and suffering, and other damages available under state law.
Depending on state law, wrongful death claims may involve funeral expenses, loss of financial support, and other damages available to survivors.
There is no established settlement range for concentrated 7-OH injury claims. Verdicts involving other kratom formulations do not reliably predict the value of an individual case.
If you or a family member suffered serious harm after using concentrated 7-OH, including an overdose, respiratory complication, seizure, or severe dependence-related injury, our attorneys can assess a potential claim.
We review the exact product, its labeling and marketing, medical records, the timing of exposure, and possible alternative causes.
We also review potential wrongful death claims involving families who lost a loved one after suspected 7-OH exposure.
Contact TorHoerman Law for a free, confidential consultation, or use the chat feature on this page to discuss your potential claim.
Concentrated 7-OH products may contain much higher amounts of the opioid-active compound than natural kratom leaf.
The FDA and medical toxicologists warn about intoxication, respiratory depression, dependence, withdrawal, and overdose. The severity of harm depends on the product and circumstances of use.
Yes. Concentrated 7-OH has been associated with serious opioid-like intoxication, including respiratory depression and overdose.
Slow breathing, unresponsiveness, or suspected overdose requires immediate emergency medical attention; naloxone may help reverse opioid-like respiratory depression but does not replace emergency care.
Severe, medically documented dependence or withdrawal may support a legal investigation if there is evidence of inadequate warnings, misleading marketing, or another actionable claim.
Withdrawal symptoms can resemble opioid withdrawal, and treatment through addiction medicine may involve individualized medication and counseling.
Dependence or withdrawal symptoms alone do not establish product liability.
The FDA has taken enforcement action against concentrated 7-OH products sold unlawfully as foods, dietary supplements, or unapproved drugs. Those actions do not amount to a blanket federal ban on natural kratom leaf.
The DEA’s October 2026 notice proposed Schedule I controls for certain concentrated compounds, while botanical kratom itself remained outside federal scheduling.
Later federal orders and state restrictions must be checked to determine a particular product’s legal status.
Using other substances does not automatically rule out a potential claim, but it may complicate the medical evidence concerning the cause of an overdose or other injury.
Our attorneys may review treatment records, toxicology results, and the circumstances of use to determine whether further investigation is appropriate.
You may qualify if you suffered serious harm after using an identifiable concentrated 7-OH product and the available evidence supports investigating a claim against a manufacturer or seller.
You can request a free case review even without the original packaging or a definitive medical opinion establishing causation.

Tor Hoerman has represented injured individuals for more than 30 years, with experience spanning individual personal injury cases and nationwide mass tort litigation. His work includes car accidents, catastrophic injuries, product liability claims, and other serious injury cases. Tor has served in court-appointed leadership roles in national litigation and tried cases involving major corporate defendants.
TorHoerman Law’s legal content is researched and written by our editorial team and attorneys for legal accuracy, clarity, and relevance. We rely on statutes, court records, government publications, medical research, and other authoritative sources when applicable. This page provides general legal information and does not constitute legal advice.
TorHoerman Law reviews its legal content for factual accuracy, current information, and relevant legal context before publication and as material developments occur. This article is provided for general informational purposes and does not constitute legal advice. For guidance about a specific case, contact TorHoerman Law.
You can learn more about this topic by visiting any of our Kratom Lawsuit pages listed below:
A serious injury can change your life.

TorHoerman Law represents people whose lives have been disrupted by serious injuries, unsafe products, and negligence. Our attorneys handle individual personal injury cases as well as national mass tort lawsuits involving major corporations.
Founded in 2009, our legal team brings more than 100 years of combined experience handling serious injury and complex civil litigation.
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!

In this case, we obtained a verdict of $495 Million for our client’s child who was diagnosed with Necrotizing Enterocolitis after consuming baby formula manufactured by Abbott Laboratories.

In this case, we were able to successfully recover $20 Million for our client after they suffered a Toxic Tort Injury due to chemical exposure.

In this case, we were able to successfully recover $103.8 Million for our client after they suffered a COX-2 Inhibitors Injury.

In this case, we were able to successfully recover $4 Million for our client after they suffered a Traumatic Brain Injury while at daycare.

In this case, we were able to successfully recover $2.8 Million for our client after they suffered an injury due to a Defective Heart Device.
A serious injury can change your life.